A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

UNION Therapeutics Strengthens Leadership Team With New Executive Appointments

October 28, 2020

UNION Therapeutics A/S (“UNION”), a privately-held clinical-stage pharmaceutical company focusing on infectious and inflammatory diseases, announced further strengthening of the leadership team.

UNION Therapeutics notes that during 2020, UNION has significantly expanded the Company’s pipeline through the advancement of two anti-viral candidates for COVID-19 (inhalation and nasal) into late-stage clinical development, and by completing the acquisition of orismilast, second-generation oral and topical PDE4 inhibitors, from LEO Pharma. Orismilast oral has demonstrated clinical proof-of-concept in psoriasis, while a topical formulation has demonstrated proof-of-concept in patients with atopic dermatitis. These expansions come in addition to ATx201, currently in Phase 2b for atopic dermatitis, bringing the number of later-stage clinical candidates to five.

Dr. Rasmus Toft-Kehler, current Chief Executive Offer (CEO) and Co-Founder of UNION Therapeutics stated: “The expansion of our pipeline has motivated the search for a CEO with a deep and strong track record in late-stage development as well as commercial experience, alongside a proven ability to execute on corporate strategies with a global team. In Dr. Kjoeller, we have found the person to lead UNION through the next chapter of growth and expansion. I am therefore proud and pleased to announce that Dr. Kjoeller, as of January 1, 2021 will be replacing me as CEO to progress UNION’s development with potential approvals and commercial opportunities in sight.”

Dr. Kjoeller added: “Having followed UNION in recent years I have become increasingly impressed with their pipeline, passion, and ability to identify and develop new improved solutions for patients in areas of significant unmet medical need. Joining UNION at this time with the opportunities that have been established through the COVID-19 program and orismilast, I cannot wait to work with the team in order to bring these candidates to patients. I am convinced that the foundation, in terms of both the pipeline and the team, has been solidly established and I look forward to leading UNION through the next chapter of development and into a sustainable success.”

Furthermore, with the addition and advancement of orismilast and the COVID-19 product candidates, UNION will increasingly focus on pharmaceutical innovation and building supply capacity and has appointed Dr. Günter Ditzinger as Chief Technology Officer. Dr. Ditzinger brings 30 years of experience from Sanofi, Novartis and most recently as the Chief Technology Officer of Swiss-based Basilea Pharmaceutica.

“Altogether, these additions to our team are important to ensure continued expansion and the ability to deliver on the ambitious goals set forth by the Board and owners of UNION, Therapeutics with the overarching vision of advancing medicine by listening and responding to patient needs.” concluded Dr. Toft-Kehler.

Other Executives In the News

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Executives on the Move

Dr A Burton Tripathi brings over two decades of Medical Device leadership experience, specializing in developing disruptive technologies, leading commercialization efforts, and facilitating M&A. Having recently served as CEO of TrueVision Systems Inc., he concluded the sale and integration of TrueVision with Alcon.
John Taylor brings more than 30 years of regulatory experience to his role at ELIQUENT, including a distinguished 20-year career at the U.S. Food and Drug Administration (FDA), where he served in multiple leadership positions, including as FDA’s Acting Deputy Principal Commissioner, FDA Counselor to the Commissioner, Acting Deputy Commissioner for Global Regulatory Operations and Policy, and Associate Commissioner for Regulatory Affairs.
Jennifer Riter comes to Kindeva from West Pharmaceutical where she spent the past 27 years in various technical and leadership roles, most recently serving as the Senior Director, Business and Technical Operations.

By using this website you agree to accept Medical Device News Magazine Privacy Policy